LongBio Pharma (Suzhou) Co., Ltd.

天辰生物医药（苏州）股份有限公司

01779.HK

Clinical-stage biopharmaceutical company based in Shanghai and Changshu, China, discovering and developing biologic antibodies for allergic and autoimmune diseases; core product LP-003, an anti-IgE antibody for seasonal allergic rhinitis, is in Phase III trials in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Related-party transactions and balances
• Chapter 18A biotech